• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Delcath plans for 1-for-350 reverse split

November 3, 2017 By Sarah Faulkner

Delcath SystemsDelcath Systems (NSDQ:DCTH) said today that it is preparing for a 1-for-350 reverse stock split, which is set to take effect on Nov. 6.

According to the terms of the reverse split, Delcath’s common stock will trade under a new symbol – DCTHD – for twenty days and then revert back to its old symbol, DCTH.

The reverse split will reduce the number of issued and outstanding shares of the company’s common stock from 490 million to 1.4 million shares.

In September, Delcath and a group of investors made an end run around the company’s shareholders with a deal that paved the way for the reverse split that stockowners have twice shot down.

“Together with our Board of Directors, we are taking these actions in the best interests of all shareholders. Regaining access to equity capital will allow us to continue investing in our Clinical Development Program and our commercial efforts in Europe,” president & CEO Jennifer Simpson wrote in a letter to the company’s shareholders.

Delcath proposed a reverse stock split in June and September of this year, but both times stockholders voted against the move. The company said those decisions left it unable to access cash otherwise available under 2016 convertible notes or to go after new equity financing.

Delcath said that it unless it made authorized shares available, it wouldn’t be able to fund its business beyond the next few months.

The company inked a deal with the 2016 convertible note holders, providing the issuance of Series C preferred shares in exchange for $500,ooo in cash. The deal gave the convertible note holders “enhanced voting rights” – sufficient to give a thumbs-up on the reverse stock split.

Filed Under: Drug-Device Combinations, Featured, Wall Street Beat Tagged With: Delcath Systems Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS